Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-U01 Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Cancers
NCT06395103Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Primary completion
- Mar 2029
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 2 trial of zilovertamab vedotin in B cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), neuroblastoma, Ewing sarcoma, sponsored by Merck & Co.. Started Aug 2024; status: recruiting.
02
Drugs
zilovertamab vedotin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)neuroblastomaEwing sarcoma
Beyond the preview
Go deeper on NCT06395103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395103.